Pricing Log in Create free account

Gyre Therapeutics, Inc. (GYRE) vs Pharming Group N.V. Sponsored ADR (PHAR)

Gyre Therapeutics, Inc. and Pharming Group N.V. Sponsored ADR are both Biotechnology companies. Gyre Therapeutics, Inc. and Pharming Group N.V. Sponsored ADR are of similar size ($681.6M and $678.6M). Gyre Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Pharming Group N.V. Sponsored ADR trades at 62.4×. Gyre Therapeutics, Inc. grew revenue faster over the last twelve months: 10.7% against 7.85%. Pharming Group N.V. Sponsored ADR has the higher net margin (2.55% vs −13.7%) and the higher return on invested capital (5.50% vs −8.51%). Across the 19 metrics below, Pharming Group N.V. Sponsored ADR leads on 12 and Gyre Therapeutics, Inc. on 7.

Valuation

Metric GYRE PHAR Biotechnology median
P/E n/m 62.40 8.50
P/S 5.26 1.36 9.71
P/B 4.29 1.85 2.13
Price to free cash flow n/m 14.53 20.82
EV/EBITDA n/m 14.36 0.64
EV/Sales 4.66 1.20 9.21
Earnings yield (3.29%) 1.60% (33.15%)
Free cash flow yield (1.16%) 6.88% (25.50%)

Profitability

Metric GYRE PHAR Biotechnology median
Gross margin 94.15% 86.54% 65.16%
Operating margin (10.53%) 5.04% 0.00%
Net margin (13.73%) 2.55% 0.00%
Free cash flow margin (6.12%) 9.38% 0.00%
Return on equity (11.75%) 3.67% (56.36%)
Return on assets (9.08%) 2.05% (48.04%)
Return on invested capital (8.51%) 5.50% 0.00%

Growth

Metric GYRE PHAR Biotechnology median
Revenue growth (TTM) 10.72% 7.85% 6.02%
EPS growth (last fiscal year) (60.00%) 125.00% 30.26%
Revenue growth, 5-year CAGR 40.96% 12.13% 9.41%
Net income growth, 5-year CAGR 0.00% (40.35%) 0.00%

Health

Metric GYRE PHAR Biotechnology median
Debt to equity 0.00 0.36 0.00
Current ratio 4.26 3.01 4.72
Net debt to EBITDA (3.74) (2.21) 0.96

Dividend

Metric GYRE PHAR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GYRE PHAR Biotechnology median
Market cap 678.62m 681.61m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack